Non classé

Artificial Intelligence-based Cell Analysis by Scailyte

The surge in AI-based solutions propels almost all industries including automotive, computing, and healthcare. MedTech startups are also beginning to utilize the high processing capability of AI to analyze millions of clinical datasets to derive insights and aid in the discovery of biomarkers and other biosignals.

For instance, startups develop AI-based algorithms to improve clinical decision-making or discover new drugs.

Swiss startup Scailyte develops in-vitro diagnostics with single-cell technologies using its proprietary single-cell data analysis platform. The startup’s biomarker discovery platform ScaiVision integrates multimodal single cell and clinical data to identify novel disease signatures.

For example, ScaiVision drives medical innovation in mass cytometry (CyTOF), high-dimensional flow cytometry, and single-cell RNA sequencing.

Read more…

Recent Posts

Unlocking Precision in Dermatology Trials: The Impact of Optical Coherence Tomography for CROs

In the dynamic landscape of dermatology research and development, Clinical Research Organizations (CROs) play a…

Testing trends Webinar – Discover all the news around the evaluation at NYSCC

Explore Trends and Innovations at NYSCC To register, click here   📅 on Tuesday May…

Roger Guillemin: Neuroscientist who Showed How the Brain Controls Hormones via Nature

Roger Guillemin identified the molecules in the brain that control the production of hormones in…